STM JOURNALS

Research & Reviews: A Journal of
Drug Design & Discovery

ISSN: 2349-9036
Volume 12, Issue 2, 2025
May–August
DOI (Journal): 10.37591/RRJoDDD

https://journals.stmjournals.com/rrjoddd

Research RRJoDDD

A Comprehensive Analysis of Novel Liposomes: Categorization, Approach, Description, and Present Formulations

Shakir Mohiuddin[1,*], Kamalesh Mistry[2], Dhananjay Mistry[3]

Abstract

Liposomes have gained attention as a promising drug delivery system, which come with the advantages of biocompatibility, ability to load hydrophilic and hydrophobic drugs, and they can function for targeted drug delivery. In this regard, this paper offers a comprehensive overview on novel liposomes, including classification, formulation strategies, detailed structures, and current pharmaceutical applications. Recent advances in liposomal drug delivery systems includes, new liposomal architectures (i.e. stealth, targeted, stimuli-responsive, hybrid liposomes) have further emerged to tackle various drug delivery issues in human therapy. These new liposomes improved pharmacokinetics, extended circulation times, and allowed targeted and controlled drug release. The study also investigates advanced formulations approaches including the incorporation of nanotechnology to enhance liposomal characteristics. This new generation of novel liposomes offers exciting new technologies but has varying challenges around scaling, reproducibility, and regulatory compliance. This paper aims to provide a holistic view of current practices and future prospects in the field, contributing valuable insights for both academic and industrial researchers.

Keywords: Liposomes, drug delivery systems, nanotechnology, formulation approaches, pharmaceutical applications

INTRODUCTION

Liposomes are nano-sized vesicular delivery systems composed of one or more bilayers of phospholipid capable of encapsulating hydrophilic or hydrophobic agents. Owing to their unique structural characteristics and biocompatibility, they are highly prospective candidates for use as pharmaceutical and biomedical agents, especially as drug delivery carriers. Since their first characterization by Alec Bangham in the early 60s, liposomes have been studied widely as drug delivery carriers to improve therapeutic efficacy, reduce side effects and improve drug stability.

The advancement in liposome technology has paved the way for novel formulations designed to address specific clinical challenges. These innovations focus on enhancing pharmacokinetics, targeting capabilities, and stability under physiological conditions. Novel liposomes, such as stealth, targeted, and stimuli-responsive variants, represent a significant evolution in this domain.

Stealth liposomes are designed to evade the immune system, thus prolonging circulation time in the bloodstream. Targeted liposomes are conjugated with specific ligands, enabling precise

***Author for Correspondence**
Shakir Mohiuddin
E-mail: shakirbhat028@gmail.com

[1]Research Scholar, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India
[2]Assistant Professor, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India
[3]Lecturer, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India

Received Date: April 03, 2025
Accepted Date: April 16, 2025
Published Date: July 09, 2025

Citation: Shakir Mohiuddin, Kamalesh Mistry, Dhananjay Mistry. A Comprehensive Analysis of Novel Liposomes: Categorization, Approach, Description, and Present Formulations. Research & Reviews: A Journal of Drug Design & Discovery. 2025; 12(2): 15–20p.

delivery to diseased tissues, while stimuli-responsive liposomes can release their payload in response to environmental triggers like pH, temperature, or enzymatic activity.

The need for more effective and patient-friendly therapeutic options has given rise to the development of these sophisticated delivery systems. Also, progress in nanotechnology and materials science played a crucial role towards liposomes structural optimization and functionalization. Liposome preparation methods have been improved (e.g., microfluidics, solvent injection, reverse-phase evaporation) leading to size uniformity and improved drug encapsulation efficiency.

Even with these advances, significant obstacles remain, including scaling up production, ensuring consistent results, and navigating regulatory processes. Further research and development are crucial to address concerns about the stability, affordability, and biological compatibility of innovative liposomes. Moreover, the path from lab to clinic is often complicated by regulatory requirements demanding thorough safety and effectiveness assessments.

This paper offers a comprehensive overview of innovative liposomes, examining their classification, preparation techniques, structural characteristics, and contemporary uses in pharmaceuticals. Furthermore, it discusses current obstacles and potential future advancements in the field, providing useful information for researchers and professionals working on drug delivery systems.

LITERATURE SURVEY

Over the years, research on liposomes for drug delivery has made substantial progress. Allen and Cullis (2013) established a foundation for understanding liposome structure and clinical use, showing their adaptability in carrying diverse therapeutic compounds [1].

Bulbake et al. (2017) highlighted liposomes' ability to improve drug absorption and decrease toxicity, especially in cancer treatment [2] to extend their time in the body and avoid immune system detection [3].

Pattni et al. (2015) investigated targeted liposomes, demonstrating that modifying their surface with specific ligands enables drug delivery to precise locations, thus reducing unwanted side effects [4]. Regarding liposome preparation, Mozafari et al. (2008) detailed various techniques, such as thin-film hydration and microfluidics, emphasizing the importance of accuracy and consistency in creating formulations for clinical use [5].

Sharma and Sharma (1997) identified limitations in early liposome designs and suggested modifications to enhance stability and drug-loading capacity [6]. More recently, Laouini et al. (2012) and Bozzuto and Molinari (2015) have examined nanoliposomes and their role in gene therapy and vaccine administration, noting their promise in contemporary medicine [7, 8].

Wang et al. (2017) further explored lipid-based nano-delivery systems, specifically focusing on improving oral absorption of drugs that dissolve poorly [9]. To summarize, the body of research emphasizes the revolutionary capabilities of liposomes in drug delivery, while also acknowledging persistent obstacles concerning large-scale production, stability, and regulatory acceptance.

The literature on liposomes as drug delivery systems has evolved significantly over the past decades. Allen and Cullis (2013) provided foundational insights into liposomal structures and their clinical applications, highlighting the versatility of liposomes in encapsulating a wide range of therapeutic agents [1]. Bulbake et al. (2017) emphasized the role of liposomes in enhancing bioavailability and reducing toxicity, particularly in cancer therapies [2].

Torchilin (2005) contributed to the understanding of stealth liposomes, which utilize polyethylene glycol (PEG) to prolong circulation time and evade immune detection. Pattni et al. (2015) explored targeted liposomes, demonstrating how surface modification with ligands can achieve site-specific drug delivery, thereby minimizing off-target effects.

In terms of preparation, Mozafari et al. (2008) discussed various methods, including thin-film hydration and microfluidic techniques, emphasizing the need for precision and reproducibility in clinical-grade formulations [5]. Sharma and Sharma (1997) highlighted limitations in early liposomal formulations and proposed modifications for improving stability and drug loading efficiency [6].

Recent studies by Laouini et al. (2012) and Bozzuto and Molinari (2015) have delved into nanoliposomes and their applications in gene therapy and vaccine delivery, emphasizing their potential in modern medicine [7, 8]. Wang et al. (2017) further explored lipid-based nano-delivery systems, focusing on enhancing oral bioavailability of poorly soluble drugs [9].

Overall, literature underscores the transformative potential of novel liposomes in drug delivery, while also pointing to ongoing challenges related to scalability, stability, and regulatory approval [1–15].

CATEGORIZATION OF NOVEL LIPOSOMES

Liposomes can be categorized based on various criteria, including size, lamellarity, surface charge, and method of preparation. Novel liposomes are primarily classified as follows.

Conventional Liposomes

- These are the simplest form of liposomes, composed of natural phospholipids and cholesterol.
- They are used to encapsulate hydrophilic and hydrophobic drugs but suffer from limited stability and rapid clearance by the reticuloendothelial system (RES).
- Their quick uptake by the RES limits their circulation time and therapeutic efficacy.

Stealth Liposomes

- Designed to overcome the limitations of conventional liposomes, stealth liposomes are surface modified with polyethylene glycol (PEG).
- This modification creates a hydrophilic shield around the liposome, reducing opsonization and phagocytosis by immune cells. As a result, they exhibit prolonged circulation time in the bloodstream, enhancing drug bioavailability and therapeutic outcomes.

Targeted Liposomes

- These liposomes are engineered with surface ligands, such as antibodies, peptides, or small molecules to recognize and bind to specific receptors on target cells.
- This targeted approach enhances drug accumulation at the disease site, minimizing off-target effects and increasing treatment efficacy. Targeted liposomes are particularly beneficial in cancer therapy, where they can selectively deliver chemotherapeutic agents to tumor cells.

Stimuli-Responsive Liposomes

- Stimuli-responsive liposomes that can respond to environmental conditions, such as pH, temperature, enzymes, or redox conditions to carry out the release of their payload.
- For example, pH-sensitive liposomes can release drug cargo in the acidic environment of the tumor or within intracellular vesicles.
- This category provides targeted and site-specific drug delivery, enhancing therapeutic efficacy and minimizing off-target effects.

Hybrid Liposomes

- These liposomes are composed of a mixture of natural and synthetic lipids to increase stability and efficiency of drug encapsulation.

- The hybrid liposomes are also based on combination with polymers and/or inorganic nanoparticles, resulting in more functional systems for enhanced targetability and controlled release.

They provide better mechanical stability and may be adapted for specific therapeutic application.

FORMULATION OF NOVEL LIPOSOMES

The formulation of novel liposomes refers to the process of creating liposomes with specific lipid compositions and utilizing various methods of preparation and drug loading techniques. Common approaches include:

Selection and Composition of Lipids

- The lipids decided governs stability, encapsulation efficiency and release profile.
- The common ingredients that they use to impart the desired characteristics include natural phospholipids, synthetic lipids, and cholesterol.

Preparation Techniques

- *Thin-Film Hydration:* Perhaps the simplest and most widely used method but can lead to heterogeneous Liposome sizes.
- *Reverse-Phase Evaporation:* This method gives large unilamellar vesicles with high encapsulation efficiency.
- *Microfluidic Approaches:* Offer precision and scalability, generating homogeneous liposomes for clinical purposes. Solvent Injection: It can produce small and uniform vesicles with high reproducibility.
- *Surface Modification:* We are trained on data till October 2023.

Cancer Therapy

- Liposomes enable targeted delivery of chemotherapeutic agents, reducing systemic toxicity and enhancing therapeutic outcomes.
- Examples include Doxil (doxorubicin liposome) and Onivyde (irinotecan liposome).

Infectious Disease Management

- Liposomes improve the bioavailability and stability of antimicrobial agents.
- AmBisome (amphotericin B liposome) is widely used for fungal infections.

Gene Therapy

- Liposomes facilitate the delivery of genetic material (DNA, RNA) into cells.
- Cationic liposomes enhance cellular uptake and protect nucleic acids from degradation.

Vaccine Delivery

- Liposomes serve as adjuvants and delivery vehicles in vaccines, improving immunogenicity and stability.
- Liposomal vaccine formulations are being explored for infectious diseases and cancer immunotherapy.

Dermal and Transdermal Applications

- Liposomes enhance drug penetration through the skin, improving efficacy in topical formulations.
- Used in cosmetic products and dermatological therapies for sustained release and improved bioavailability.

CHALLENGES AND FUTURE PROSPECTS

Despite the advancements, novel liposomes face several challenges.

Scalability and Manufacturing

- Consistent and scalable production processes are required for commercial viability.
- Advanced techniques, like microfluidics, offer potential solutions but require further optimization.

Stability and Shelf-life

- Liposomes are prone to aggregation, fusion, and degradation, impacting their efficacy.
- Developing robust storage and stabilization strategies is critical.

Regulatory and Clinical Considerations

- Stringent regulatory requirements necessitate comprehensive safety and efficacy evaluations.
- Standardizing evaluation protocols can facilitate smoother regulatory approval processes.

Future Innovations

- Research into novel lipid materials, stimuli-responsive systems, and hybrid technologies is ongoing.
- The integration of artificial intelligence and machine learning could optimize formulation and predict therapeutic outcomes.

CONCLUSIONS

Liposomes, as a cutting-edge drug delivery system, provide targeted, controlled, and efficient Therapeutic delivery. Despite remarkable progress in creating advanced liposomal formulations, hurdles persist in scaling up production, ensuring stability, and navigating regulatory pathways. Overcoming these challenges will necessitate ongoing research and partnerships among academic institutions, industries, and regulatory agencies. The future looks bright for liposomal drug delivery, with potential breakthroughs set to transform therapeutic practices and enhance patient well-being.

REFERENCES

1. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48. https://doi.org/10.1016/j.addr.2012.09.037
2. Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: An updated review. Pharmaceutics. 2017;9(2):12.
3. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145–60.
4. Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem Rev. 2015;115(19):10938–66.
5. Mozafari MR, Johnson C, Hatziantoniou S, Demetzos C. Nanoliposomes and their applications in food and pharmaceutical industries. Nanoscience. 2008;4:357–66.
6. Sharma A, Sharma US. Liposomes in drug delivery: Progress and limitations. Int J Pharm. 1997;154(2):123–40.
7. Laouini A, Jaafar-Maalej C, Sfar S, Charcosset C, Fessi H. Liposomes: Preparation, characterization, and applications. Genet Eng Biotechnol J. 2012;1(2):147–68.
8. Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine. 2015;10:975–99.
9. Wang T, et al. Recent progress on lipid-based nano-delivery systems for enhancing oral bioavailability of poorly water-soluble drugs. 2017.
10. Zhang H, et al. Liposomal nanocarriers for breast cancer chemotherapy: Safety and efficacy assessment. J Control Release. 2010;144(1):73–81.
11. Kulkarni PR, Yadav JD, Vaidya KA, Gandhi PV, Pardeshi CV. The liposome: A new drug delivery system. Int J Pharm Sci Res. 2015;6(7):1324–32.
12. Immordino ML, Brusa P, Rocco F, Arpicco S, Ceruti M, Cattel L. Preparation, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Control Release. 2006;113(2):153–63.
13. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Challenges and advances in liposome-mediated drug delivery. Front Pharmacol. 2015;6:286.

14. Immordino ML, Dosio F, Cattel L. Stealth liposomes: Review of the basic science, rationale, and clinical applications. Int J Nanomedicine. 2006;1(3):297–306.
15. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: Classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102.